Study Condition(s): Type 2 Diabetes
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes (T2DM)
Study Alias: GPGA
The 3 main purposes of this study are to determine the safety of tirzepatide and any side effects that might be associated with it, how much tirzepatide gets into the bloodstream and how long it takes the body to get rid of it and how tirzepatide affects the levels of blood sugar. Each participant will enroll in only one part. This study is for research purposes only, and is not intended to treat any medical condition.
The results of this study are not yet available.
Here you can find out a bit more about the requirements for volunteers who took part in this study
- Participant must be diagnosed with T2DM at least 1 year before enrollment for Part C
- Participant with T2DM (Part C only) must have T2DM controlled with diet and exercise alone or are stable on a single oral antidiabetic medication (metformin for at least 30 days or sulfonylureas. Participants receiving sulfonylureas may participate only if this treatment is stopped for at least 6 weeks before dosing with study drug
- Participant must not have a history or presence of pancreatitis (history of chronic pancreatitis or idiopathic acute pancreatitis)
- Participant with T2DM (Part C only) must not have had more than 1 episode of severe low blood sugar within 6 months before entry into the study or has a history of being unaware or poorly recognizing symptoms of low blood sugar
- Participant in Part C must not have known allergies to tirzepatide, GLP-1 analogs, or related compounds, or acetaminophen